CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- c/side, a cybersecurity company specializing in browser-side third-party scripts, is now available in AWS Marketplace, a digital catalog with ...